Daubert v. Merrell Dow Pharmaceuticals

(redirected from 509 U.S. 579)
A lawsuit by brought by J. Daubert, who was born with limb-reduction defects, alleging that the cause of his disability was Bendectin, produced by Merrell Dow Pharmaceuticals
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
(20.) See Daubert, 509 U.S. 579,595 (1993) (quoting Jack B.
CABINING JUDICIAL DISCRETION OVER FORENSIC EVIDENCE WITH A NEW SPECIAL RELEVANCE RULE
Merrell Dow Pharm., Inc., 509 U.S. 579, 592 (1993) (citations omitted) ("Unlike an ordinary witness,...
THE BEST INSURANCE AGAINST MISCARRIAGES OF JUSTICE CAUSED BY JUNK SCIENCE: AN ADMISSIBILITY TEST THAT IS SCIENTIFICALLY AND LEGALLY SOUND
Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993) to be admissible."
IoT Devices Becoming More Important in Criminal Investigations
Merrell Dow Pharm., Inc., 509 U.S. 579, 587 (1993) (citing Beech Aircraft Corp.
Defending Daubert: it's time to amend Federal Rule of Evidence 702
Merrell Dow Pharm., Inc., 509 U.S. 579, 597 (1993) (holding that judges should act as a gatekeeper in regard to the reliability of expert evidence).
We the people: juries, not judges, should be the gatekeepers of expert evidence
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 597 (1993), the Court addressed four factors to consider in determining the admissibility of expert witness testimony.
Adoption of Daubert in the amendment to F.S. [section] 90.702 tightens the rules for admissibility of expert witness testimony
Merrell Dow Pharm., Inc., 509 U.S. 579, 587 (1993) (abolishing standard of admissibility adopted in Frye for a more relaxed standard).
Firearms identification: the need for a critical approach to, and possible guidelines for, the admissibility of "ballistics" evidence
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593 (1993), an opinion that was extended to all expert testimony in a subsequent Supreme Court case and that has been specifically applied to appraisers on numerous occasions.
Comments on "A Message from the Editor-in-Chief"
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), augmented Frye with a number of other factors that federal courts are to consider in determining whether such information is sufficiently reliable to be admitted into evidence.
Virginia Supreme Court rules insufficient foundation provided by Commonwealth to permit plethysmograph testing conducted as part of psychosexual evaluation to be admitted into evidence at sentencing hearing
Merrell Dow Pharmaceuticals (509 U.S. 579 [1993]), which led federal trial judges to become "gatekeepers" of scientific evidence.
Analysis of bank dye evidence and the challenges of Daubert hearings
Merrell Dow Pharms., Inc., 509 U.S. 579 (1993), and the two decisions further refining the Daubert admissibility standard: Gen.
Get the most from engineering experts: success at trial depends on how effectively your engineering experts present their methodology and communicate to the jury why and how a defective product injured your client. Thorough preparation of these experts is key
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), together with General Electric Co.
Flexible standards, deferential review: Daubert's legacy of confusion
Medical browser ?
Full browser ?